MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Patient and Care Partner Perspectives on a Community-Based Outpatient Palliative Care Intervention for Parkinson’s Disease and Related Disorders‬

    M. Bock, R. Ayele, Z. Macchi, M. Dini, M. Katz, B. Kluger (San Francisco, USA)

    Objective: To understand patient and care partner perspectives on a community-based outpatient palliative care intervention for patients with Parkinson’s disease and related disorders (PDRD). Background:…
  • MDS Virtual Congress 2021

    A Milestone-based approach to monitoring disease progression in Parkinson’s disease

    M. Brumm, A. Siderowf, T. Simuni, C. Caspell-Garcia, L. Chahine, T. Foroud, V. Arnedo, A. Reimer, C. Tanner, K. Poston, D. Weintraub, S. Hutten, K. Kieburtz, K. Marek, C. Coffey (Iowa City, USA)

    Objective: We used Parkinson Progression Marker Initiative (PPMI) data to assess the frequency of clinically meaningful disease milestones and examine baseline predictors of reaching these…
  • MDS Virtual Congress 2021

    The ADOPTION (eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs) study in Parkinson’s disease: design and rationale of a randomized prospective, open-label exploratory trial

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This study aims to explore the potential of opicapone (OPC) to optimize levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) as first-line approach to treat wearing-off in…
  • MDS Virtual Congress 2021

    Re-thinking enrollment of Deep Brain Stimulation patients in Parkinson’s Disease Clinical Trials

    J. Jimenez-Shahed, J. Rosenow, S. Miocinovic, L. Luo, C. Aquino, D. Corcos, P. Agarwal (New York, USA)

    Objective: To report on a survey of Parkinson’s disease (PD) experts on the inclusion of PD patients with deep brain stimulation (DBS) in clinical trials.…
  • MDS Virtual Congress 2021

    The Role of the PD Diary Trainer/Reviewer in Parkinson’s Disease Clinical Trials

    C. Mañeru, S. Meyer (Barcelona, Spain)

    Objective: To examine the experience profile of PD Diary raters in clinical trials Background: The Parkinson’s Disease (PD) Home Diary (Hauser, 2000)1 is a widely…
  • MDS Virtual Congress 2021

    Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial

    D. Pourzinal, A. Bakker, G. Byrne, K. Mcmahon, J. O'Sullivan, R. Adam, A. Lehn, D. Copland, J. Yang, G. Pontone, T. Au, R. Littleford, M. Chatfield, Z. Mari, N. Dissanayaka (Herston, Australia)

    Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…
  • MDS Virtual Congress 2021

    Impact of specialized light therapy in Parkinson’s disease on MDS-UPDRS parts 1-3 subscales

    B. Wyman, S. Hendrix, S. Hennessey, S. Dickson, J. Groves, W. Croft, D. Adams (Draper, USA)

    Objective: An exploratory analysis to examine the MDS-UPDRS 1-3 subitems of PD patients who underwent specialized light therapy (SLT) to assess the breadth of impact…
  • MDS Virtual Congress 2021

    Effect of oxytocin on response inhibition in Parkinson´s disease: a pilot study

    F. Carbone, P. Ellmerer, S. Spielberger, M. Peball, V. Sidoroff, M. Ritter, K. Seppi, W. Poewe, A. Djamshidian (Innsbruck, Austria)

    Objective: To observe the effect of oxytocin (OXT) on response inhibition in Parkinson´s disease (PD) patients using dedicated saccadic tasks. Background: Cumulating evidence has shown…
  • MDS Virtual Congress 2021

    Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

    I. Frouni, SG. Nuara, D. Bédard, A. Hamadjida, JC. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with ALX-5407 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism severity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…
  • MDS Virtual Congress 2021

    Neuroprotective Epigenetic and DNA-Repair Molecular Mechanisms of Acetyl-L-Carnitine and Astaxanthin Against 6-OHDA Induced Parkinsonism in Aged Rats

    S. Kumar, P. Kumar, A. Williams, M. Anifowose, K. Ponnusamy (Puducherry, India)

    Objective: Present study was designed to delineate the neuroprotective epigenetic and DNA-damage-repair molecular mechanisms of acetyl-L-carnitine (ALC) and astaxanthin (ASX) against  6-OHDA-induced neurotoxicity in aged…
  • « Previous Page
  • 1
  • …
  • 79
  • 80
  • 81
  • 82
  • 83
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley